SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
+1.73%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$124M
AUM Growth
+$124M
(-22%)
Cap. Flow
-$70.5M
Cap. Flow
% of AUM
-56.93%
Top 10 Holdings %
Top 10 Hldgs %
58.94%
Holding
58
New
20
Increased
13
Reduced
18
Closed
6
Top Buys
| 1 |
TELA Bio
TELA
|
$3.75M |
| 2 |
Inhibikase Therapeutics
IKT
|
$3.68M |
| 3 |
Inovio Pharmaceuticals
INO
|
$1.92M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$1.91M |
| 5 |
CalciMedica
CALC
|
$1.66M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$34.1M |
| 2 |
ADMA Biologics
ADMA
|
$10.8M |
| 3 |
Kezar Life Sciences
KZR
|
$9.28M |
| 4 |
Galapagos
GLPG
|
$7.66M |
| 5 |
Royalty Pharma
RPRX
|
$6M |
Sector Composition
| 1 | Healthcare | 99.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ADMA Biologics
ADMA
$4.12B
| $21.3M | 17.18% |
1,241,032
-628,968
| -34% | -$10.8M |
|
2
Evolus
EOLS
$494M
| $14M | 11.27% |
1,264,651
-105,170
| -8% | -$1.16M |
|
|
3
TELA Bio
TELA
$70.5M
| $7.11M | 5.74% |
2,353,099
+1,243,099
| +112% | +$3.75M |
|
|
4
Galapagos
GLPG
$2.07B
| $5.5M | 4.44% |
200,000
-278,659
| -58% | -$7.66M |
|
5
Zevra Therapeutics
ZVRA
$509M
| $4.98M | 4.02% |
597,700
-102,300
| -15% | -$853K |
|
6
Verastem
VSTM
$569M
| $4.5M | 3.63% |
870,000
-440,287
| -34% | -$2.28M |
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $4.04M | 3.26% |
220,000
+23,105
| +12% | +$424K |
|
|
OPTN
8
DELISTED
OptiNose
OPTN
| $3.93M | 3.17% |
588,657
-5,099,933
| -90% | -$34.1M |
|
9
Anika Therapeutics
ANIK
$135M
| $3.92M | 3.17% |
238,222
+48,914
| +26% | +$805K |
|
10
Indivior
INDV
$3.03B
| $3.79M | 3.06% |
305,000
+35,000
| +13% | +$435K |
|
11
Establishment Labs
ESTA
$1.2B
| $3.69M | 2.98% |
80,002
+5,002
| +7% | +$230K |
|
|
12
Inhibikase Therapeutics
IKT
$134M
| $3.68M | 2.97% |
+1,132,388
| New | +$3.68M |
|
13
UroGen Pharma
URGN
$900M
| $3.45M | 2.79% |
324,324
+43,979
| +16% | +$468K |
|
14
Xoma
XOMA
$392M
| $3.3M | 2.67% |
125,700
-69,396
| -36% | -$1.82M |
|
15
Day One Biopharmaceuticals
DAWN
$769M
| $2.98M | 2.4% |
235,000
+29,325
| +14% | +$372K |
|
16
Ironwood Pharmaceuticals
IRWD
$214M
| $2.87M | 2.32% |
648,785
-351,215
| -35% | -$1.56M |
|
17
scPharmaceuticals
SCPH
$295M
| $2.42M | 1.95% |
683,530
-95,344
| -12% | -$338K |
|
18
Surrozen
SRZN
$104M
| $1.97M | 1.59% |
137,200
+27,200
| +25% | +$390K |
|
|
19
Inovio Pharmaceuticals
INO
$126M
| $1.92M | 1.55% |
+1,050,000
| New | +$1.92M |
|
|
20
Enanta Pharmaceuticals
ENTA
$180M
| $1.91M | 1.54% |
+331,900
| New | +$1.91M |
|
21
Myomo
MYO
$39.7M
| $1.77M | 1.43% |
274,426
+174,426
| +174% | +$1.12M |
|
|
22
CalciMedica
CALC
$37.7M
| $1.66M | 1.34% |
+468,793
| New | +$1.66M |
|
23
Aclaris Therapeutics
ACRS
$209M
| $1.65M | 1.33% |
663,405
-1,795,468
| -73% | -$4.45M |
|
|
PROF
24
Profound Medical
PROF
$134M
| $1.5M | 1.21% |
+200,000
| New | +$1.5M |
|
25
Jazz Pharmaceuticals
JAZZ
$7.75B
| $1.23M | 0.99% |
10,000
-45,000
| -82% | -$5.54M |
|